Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2357–2361. doi: 10.1128/aac.38.10.2357

Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori.

H Xia 1, C T Keane 1, S Beattie 1, C A O'Morain 1
PMCID: PMC284744  PMID: 7840570

Abstract

Susceptibilities of 121 clinical Helicobacter pylori strains to metronidazole were determined by both a 5-micrograms metronidazole disk diffusion test and a plate dilution method in duplicate and after different periods of incubation. The distribution of MICs of metronidazole against H. pylori among the strains was found to be bimodal. The diameters of inhibitory zones obtained by the disk diffusion test and the MICs obtained by the plate dilution method correlated well, especially after 4 days of incubation (r = 0.77). An inhibitory zone diameter of 20 mm was found to correspond to a MIC of 8 micrograms/ml and is recommended as a suitable zone for differentiating susceptibility and resistance with a 5-micrograms metronidazole disk. Three interpretive categories of susceptibility results were defined; strains with inhibitory zone diameters of more than 26 mm were defined as susceptible (MIC, < 4 micrograms/ml), strains with zone diameters of 20 to 26 mm were deemed intermediate (MIC, 4 to 8 micrograms/ml), and those with zone diameters of less than 20 mm were deemed resistant (MIC, > 8 micrograms/ml). Furthermore, 76 H. pylori-positive patients with duodenal ulcers or nonulcer dyspepsia were treated with a 1 week of triple therapy (colloidal bismuth subcitrate, metronidazole, and tetracycline). H. pylori strains were isolated before treatment from antral biopsies from those patients, and the metronidazole susceptibilities of the strains were determined by the disk diffusion test. H. pylori status was evaluated again 4 weeks after completion of treatment. The eradication rates for susceptible, intermediate, and resistant strains were 95.9% (47 of 49), 62.5% (5 of 8), and 52.6% (10 of 19), respectively. It is included that the 5-micrograms disk diffusion test is easy to perform and gives final results similar to those of the plate dilution method. The three interpretive categories of susceptibility may be of benefit for clinical choice of chemotherapy in eradicating H. pylori.

Full text

PDF
2357

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becx M. C., Janssen A. J., Clasener H. A., de Koning R. W. Metronidazole-resistant Helicobacter pylori. Lancet. 1990 Mar 3;335(8688):539–540. doi: 10.1016/0140-6736(90)90772-w. [DOI] [PubMed] [Google Scholar]
  2. Bell G. D., Powell K., Burridge S. M., Pallecaros A., Jones P. H., Gant P. W., Harrison G., Trowell J. E. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992 Aug;6(4):427–435. doi: 10.1111/j.1365-2036.1992.tb00556.x. [DOI] [PubMed] [Google Scholar]
  3. Cederbrant G., Kahlmeter G., Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother. 1993 Jan;31(1):65–71. doi: 10.1093/jac/31.1.65. [DOI] [PubMed] [Google Scholar]
  4. Coremans G., Tack J., Vantrappen G., Janssens J., Annese V. Is the irritable bowel really irritable? Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):39–40. [PubMed] [Google Scholar]
  5. DeCross A. J., Marshall B. J., McCallum R. W., Hoffman S. R., Barrett L. J., Guerrant R. L. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol. 1993 Aug;31(8):1971–1974. doi: 10.1128/jcm.31.8.1971-1974.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glupczynski Y., Burette A., De Koster E., Nyst J. F., Deltenre M., Cadranel S., Bourdeaux L., De Vos D. Metronidazole resistance in Helicobacter pylori. Lancet. 1990 Apr 21;335(8695):976–977. doi: 10.1016/0140-6736(90)91043-a. [DOI] [PubMed] [Google Scholar]
  7. Glupczynski Y., Burette A. Eradicating Helicobacter pylori. Lancet. 1992 Jan 4;339(8784):54–55. [PubMed] [Google Scholar]
  8. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  9. Goodwin C. S., Marshall B. J., Blincow E. D., Wilson D. H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988 Feb;41(2):207–210. doi: 10.1136/jcp.41.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Haas C. E., Nix D. E., Schentag J. J. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother. 1990 Sep;34(9):1637–1641. doi: 10.1128/aac.34.9.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hirschl A. M., Hirschl M. M., Rotter M. L. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother. 1993 Jul;32(1):45–49. doi: 10.1093/jac/32.1.45. [DOI] [PubMed] [Google Scholar]
  12. Knapp C. C., Ludwig M. D., Washington J. A. In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion. Antimicrob Agents Chemother. 1991 Jun;35(6):1230–1231. doi: 10.1128/aac.35.6.1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. O'Riordan T., Mathai E., Tobin E., McKenna D., Keane C., Sweeney E., O'Morain C. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 1990 Sep;31(9):999–1002. doi: 10.1136/gut.31.9.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pavicić M. J., Namavar F., Verboom T., van Winkelhoff A. J., De Graaff J. In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations. Antimicrob Agents Chemother. 1993 May;37(5):1184–1186. doi: 10.1128/aac.37.5.1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Prantera C., Berto E., Scribano M. L. Mycobacteria and subgroups of patients in Crohn's disease. Ital J Gastroenterol. 1991 Jan;23(1):49–51. [PubMed] [Google Scholar]
  16. Prantera C., Berto E., Scribano M. L. Mycobacteria and subgroups of patients in Crohn's disease. Ital J Gastroenterol. 1991 Jan;23(1):49–51. [PubMed] [Google Scholar]
  17. Rautelin H., Seppälä K., Renkonen O. V., Vainio U., Kosunen T. U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992 Jan;36(1):163–166. doi: 10.1128/aac.36.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Xia H. X., Daw M. A., Beattie S., Keane C. T., O'Morain C. A. Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients. Ir J Med Sci. 1993 Mar;162(3):91–94. doi: 10.1007/BF02942098. [DOI] [PubMed] [Google Scholar]
  19. Xia H. X., English L., Keane C. T., O'Morain C. A. Enhanced cultivation of Helicobacter pylori in liquid media. J Clin Pathol. 1993 Aug;46(8):750–753. doi: 10.1136/jcp.46.8.750. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES